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Familial dysautonomia (FD) is a severe hereditary sensory and autonomic neuropathy, and all patients with FD have a splice mutation in the
IKBKAP gene. The FD splice mutation results in variable, tissue-specific skipping of exon 20 in IKBKAP mRNA, which leads to reduced
IKAP protein levels. The development of therapies for FD will require suitable mouse models for preclinical studies. In this study, we report the
generation and characterization of a mouse model carrying the complete human IKBKAP locus with the FD IVS20+6T→C splice mutation. We
show that the mutant IKBKAP transgene is misspliced in this model in a tissue-specific manner that replicates the pattern seen in FD patient tissues.
Creation of this humanized mouse is the first step toward development of a complex phenotypic model of FD. These transgenic mice are an ideal
model system for testing the effectiveness of therapeutic agents that target the missplicing defect. Last, these mice will permit direct studies of
tissue-specific splicing and the identification of regulatory factors that play a role in complex gene expression.
© 2007 Elsevier Inc. All rights reserved.Keywords: Familial dysautonomia; mRNA splicing; Transgenic modelFamilial dysautonomia (FD; Riley–Day syndrome, here-
ditary sensory and autonomic neuropathy type III, OMIM
223900) is a debilitating disorder that is due to the poor
development, poor survival, and progressive degeneration of
the sensory and autonomic nervous system [1,2]. The loss of
neuronal function in FD has many repercussions, with patients
having gastrointestinal dysfunction, abnormal respiratory
responses to hypoxic and hypercarbic states, scoliosis, gastro-
esophageal reflux, vomiting crises, lack of overflow tears,
inappropriate sweating, and postural hypotension. Despite
recent advances in the management of FD, the disease is
inevitably fatal, with only 50% of patients reaching the age of
40 [3]. The clinical features of FD are due to a striking,
progressive depletion of unmyelinated sensory and autonomic
neurons. Fetal development and postnatal maintenance of dorsal
root ganglion neurons are abnormal, and slow progressive⁎ Corresponding author. Fax: +1 617 726 5735.
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doi:10.1016/j.ygeno.2007.05.012degeneration is evidenced by continued neuronal depletion with
increasing age [1].
FD is a recessive genetic defect with a high carrier frequency
in the Ashkenazi Jewish population that ranges from 1 in 32 [4]
to as high as 1 in 18 in those of Polish descent [5]. Recent studies
identified mutations in the gene IKBKAP as the cause of familial
dysautonomia [6,7]. Three FD-causing mutations have been
identified: an intronic noncoding point mutation, IVS20+6T→C
(c. 2204+6T→C, NM_003640.2), which leads to variable
skipping of exon 20, and two missense mutations, R696P (four
patients) and P914L (one non-Jewish patient) [6–8]. Impor-
tantly, all FD patients identified to date possess at least one copy
of the IVS20+6T→C mutation; 99.8% of patients are homo-
zygous for this mutation, and five patients are compound
heterozygotes with a missense mutation [6–8]. The result of the
IVS20+6T→C mutation is a decrease in splicing efficiency that
causes skipping of exon 20 in the IKBKAP message. This
skipping event results in a frameshift and the introduction of a
premature termination codon. All FD cells express both wild-
type mRNA (WT) and mutant mRNA (MU) that lacks exon 20.
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the 5′ splice site of exon 20. It is important to point out that FD is
a recessive disease and there is no evidence that the mutant
message is translated. We have previously shown that the mutant
message is likely targeted for nonsense-mediated decay, and we
can measure the relative amounts of WT:MU isoforms in FD cell
lines and tissues [9]. This ratio varies between tissues, with the
greatest amount of MU isoform produced in tissues from the
central and peripheral nervous system [10]. Therefore, the
pathogenic result of the IKBKAP splice mutation is a tissue-
specific reduction in normal IKAP protein below a tolerable
threshold. The neuronal phenotype of this disease suggests that
the IKBKAP levels in specific neurons fall below the threshold
required for normal development and maintenance. The IKAP
protein is a subunit of the highly conserved Elongator complex,
which is involved in transcriptional elongation [11]. RNA
interference studies have shown that depletion of IKAP, and
therefore Elongator, results in reduced transcription of a number
of target genes via histone H3 hypoacetylation [12]. A number of
these target genes play a role in cell motility, and FD patient cells
were shown to be defective in standard cell migration assays. It is
likely, therefore, that tissue-specific depletion of IKAP due to
defective mRNA splicing leads to transcriptional dysregulation
and impaired cell motility, which may be responsible for the
neuropathology seen in FD.
The study of alternative splicing and of disease-causing
splicing mutations has highlighted the importance of cis-acting
control sequence elements that contribute to exon recognition
and correct splicing, as reviewed in [13–15]. In addition to the
well-characterized canonical sequences of the branch point and
the 5′ and 3′ splice sites, lesser defined enhancer and silencer
elements in both exonic and intronic sequences have also been
widely reported. The regulation of splicing is a complicated,
multilayered process, and despite recent progress in the field,
the “splicing code” that dictates when an exon is skipped or
included in the final transcript is still poorly understood.
Detailed studies of IKBKAP missplicing have shown that
IKBKAP exon 20 splicing regulation is no exception; exon 20
inclusion is delicately balanced and a variety of sequence
elements contribute to the inclusion/exclusion decision [16,17].
The characterization of the IKBKAP splice defect in FD
suggests that this disease is potentially treatable using strategies
that improve exon 20 inclusion and subsequently increase the
amount of normal IKAP protein in FD patients. Although FD is
a developmental disorder, patients show continued neuronal
degeneration throughout life, which leads to progressive ataxia
and dementia in adulthood. An increase in IKAP at an early age
might slow neuronal loss and reduce the symptoms that appear
as patients mature. As part of a National Institute of Neuro-
logical Disorders and Stroke-sponsored drug screen, we
previously identified the plant cytokinin kinetin as a potential
therapeutic agent for FD [9]. We have shown that this small
molecule dramatically improves IKBKAP exon 20 inclusion
and consequently raises IKAP protein levels in cultured FD
patient lymphoblast and fibroblast cell lines.
To examine the efficacy of kinetin and other potential thera-
peutic agents, it is desirable to have an accurate murine modelfor use in preclinical trials. In this study we describe the creation
of an accurate IKBKAP splicing model. We created several
transgenic mice expressing either human wild-type IKBKAP or
FD (IVS20+6T→C) IKBKAP from a human BAC. We show
that the presence of the FD mutation in the BAC causes miss-
plicing of human IKBKAP in mice and that the efficiency of
exon inclusion varies in a tissue-specific manner that closely
models that seen in FD patients. Additionally, we show in tissue
culture experiments that missplicing of human IKBKAP in
mouse cells can be corrected by kinetin treatment, demonstrat-
ing conservation of cellular factors required for kinetin activity.
The transgenic mouse model described in this study is an
important and accurate system for preclinical testing of kinetin
and other potential therapeutic agents aimed at improving
IKBKAP splicing. Further, it demonstrates conservation of
tissue-specific alternative splicing and provides a unique model
system for unraveling this complex cellular process.
Results
Introduction of the IVS20+6T→C mutation into the human
BAC
In our previous in vitro studies of IKBKAP splicing we
showed that any number of slight sequence changes can alter
splicing efficiency, highlighting the complexity of the control
mechanism of exon 20 inclusion [17]. Splicing of mouse Ikb-
kap exon 20, in the context of both the mouse and the human
sequences, is more efficient, and introduction of the FD mu-
tation into the mouse Ikbkap gene does not result in exon
skipping (data not shown), and therefore we pursued a trans-
genic rather than a knock-in model. To maximize the chance of
accurately recapitulating the endogenous splicing mechanism,
it is necessary to include in the transgene the complete genomic
sequence including all intronic sequences and potential regu-
latory regions. We used the human BAC clone RP11-234B17,
which contains the complete sequence of IKBKAP and appro-
ximately 20 and 80 kb of genomic sequence downstream and
upstream, respectively (Fig. 1A). Also present in this BAC,
located in close proximity to IKBKAP, are three other genes,
ACTL7B, ACTL7A, and C9orf6, and the 3′ end of a fourth
gene, CTNNAL1. To introduce the subtle FD point mutation
into the BAC without altering any other sequence elements, we
used a shuttle vector/recA-dependent homologous recombina-
tion method adapted from Lalioti and Heath [18]. This strategy
involves two rounds of homologous recombination, the first
involving positive selection for an integration event involving
the BAC and a shuttle vector containing the homologous
sequence bearing the mutation of interest. Fig. 1B shows a
representation of the shuttle vector pKO3-KAN-FD, containing
a 1.7-kb fragment of IKBKAP bearing the IVS20+6T→C
mutation, which was created for this recombination strategy.
The second step involves counterselection for a recombination
event that resolves the shuttle vector/BAC co-integrant,
removing the vector sequences and leaving the desired
mutation within the BAC sequence in approximately 50% of
the resolved constructs. The presence of the FD mutation in the
Fig. 1. (A) Schematic diagram representing the 172-kb RP11-234B17 BAC clone insert. The approximate sizes and locations of the complete genes IKBKAP, ACTL7B,
ACTL7A, and C9orf6, and the 3′ end of CTNNAL1, are indicated. (B) Schematic representation of the shuttle vector pKO3-KAN-FD constructed for the homologous
recombination strategy. The important features of pK03-KAN-FD are the 1767-bp genomic fragment of the IKBKAP gene including the FD IVS20+6T→C mutation;
RepA (pSC101-ts), the temperature sensitive origin of replication; SacB, the levansucrase gene, a counterselectable marker; and Kan, a positive-selectable marker for
kanamycin resistance. (C) Sequence analysis of exon 20 5′ splice site, in the unmodified RP11-234B17 clone, an intermediate co-integrant clone, and the modified FD
BAC, being the IVS20+6T→C mutation. The intermediate co-integrant clone contains both the wild-type sequence and the FD mutation and hence
appears “heterozygous” for T/C at position 6 of intron 20.
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and the integrity of the resolved BAC was confirmed by end
sequencing with T7 and Sp6 primers and by restriction digest
comparison to the original unaltered RP11-234B17 clone (data
not shown).
Transient expression of wild-type and mutant FD IKBKAP in
mouse N2A cells
Prior to generation of transgenic mice by microinjection of
the BAC DNA, we tested for expression and splicing fidelity of
both the wild-type and the FD BAC DNA. Purified DNA was
transiently expressed in mouse N2A (neuroblastoma) cells.
Seventy-two hours posttransfection, N2A cells were harvested
and RNA was extracted. Using RT-PCR with verified human-
specific primers, expression of IKBKAP was confirmed from
both the wild-type and the FD BACs (Fig. 2A). Analysis of
exon 20 splicing in IKBKAP expressed from the BAC DNA
revealed that the wild-type BAC produced only the WT
isoform, while the modified FD BAC produced both the WT
and the MU spliced isoforms. This confirmed that the
introduction of the FD IVS20+6T→C mutation in the human
BAC leads to exon 20 skipping of IKBKAP when transiently
expressed in mouse cells, modeling the effect of this mutation
seen in FD patients.Kinetin improves IKBKAP splicing in mouse N2A cells
We tested whether the potential FD therapeutic drug kinetin
could improve exon 20 inclusion in IKBKAP transcripts ex-
pressed in mouse cells. N2A cells transiently expressing IKB-
KAP from the FD BAC were treated with 100 μM kinetin, and
splice products were analyzed by RT-PCR (Fig. 2B). An
improvement in exon 20 inclusion was observed in kinetin-
treated samples, demonstrating that the cellular mechanism by
which kinetin alters splicing is conserved between these two
species. This finding is particularly encouraging as it suggests
that mice expressing the human FD IKBKAP will be exploitable
as models to test kinetin and other agents in preclinical animal
trials.
Creation and characterization of humanized IKBKAP
transgenic mice
After successfully detecting human IKBKAP expression
from the BAC sequence in mouse cells, both the wild-type and
the modified FD BAC constructs were used to generate trans-
genic animals by C57/BL6 oocyte microinjection. The initial
microinjections yielded five FD and one wild-type (TgFD1–5
and TgWT1) founder animals, which were identified by PCR
screening with primers specific to the human gene and con-
Fig. 2. (A) RT-PCR analysis on ethidium bromide-stained agarose gels of exon 20 splicing in mouse N2A cells transiently expressing human IKBKAP from increasing
amounts (1–4 μg) of transfected wild-type and FD BAC DNA. The wild-type BAC expresses only the WT isoform, while the modified FD BAC expresses both the
WTand the MU isoform. (B) Analysis of exon 20 splicing in kinetin-treated and untreated N2A cells expressing human IKBKAP from the FD BAC. An increase in the
percentage of WT isoform is detectable with kinetin treatment. Also shown are untransfected mouse N2A and human HEK cells, demonstrating the specificity of the
primers to amplify only human IKBKAP. (C) RT-PCR of N2A and HEK transfection samples as in (B) using mouse-specific Ikbkap primers. All transfections and
treatments are shown in duplicate. (D) Sequence analysis of RT-PCR products of FD BAC showing presence of both wild-type and mutant spliced IKBKAP transcripts.
Sequence at the junction of exons 19 and 20 (top) and exons 20 and 21 (middle) indicates the inclusion of exon 20 in the WT isoform. The bottom shows the sequence
of the exon 19 and 21 junction confirming the absence of exon 20 in the mutant splice isoform.
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number was estimated by both quantitative PCR analysis and
Southern blotting against known quantities of BAC DNA and
human genomic DNA [19] (Fig. 3). Evaluation of human
IKBKAP expression and splicing in mice carrying the transgene
was carried out by RT-PCR on total RNA extracted from heart,
lung, liver, kidney, eye, and brain tissue. We detected ex-
pression of human IKBKAP in three of the six founder mice.
The lack of expression in three of the founders is not unexpected
and may be due to a number of factors, including copy number,
insertion location, and disruption of transgene integrity, all ofwhich can potentially affect BAC transgene expression [20].
Expression of human IKBKAP was detected in one wild-type
IKBKAP transgenic animal (TgWT1) and two FD IKBKAP
transgenic animals (TgFD1, TgFD2). Analysis of the human
transcripts expressed from the wild-type IKBKAP transgene in
TgWT1 mice shows production of only the WT isoform (Fig.
4A), while transcripts expressed from the FD transgene in
TgFD1 and TgFD2 showed production of both the WT and the
MU (exon 20 skipped) isoforms. Importantly, the tissue-specific
variability seen in the splicing patterns in these transgenic mice
models what we previously observed in human FD patient
Fig. 3. (Top) Estimated copy number from six transgenic IKBKAP mice, calculated by Southern blotting and quantitative PCR of genomic DNA using human DNA
(two copies) as a standard. *Multiple bands of varying sizes were present in the Southern blot, suggesting the integrity of the BAC was disrupted in this transgenic
mouse. (Bottom) Southern blot analysis of transgenic mouse genomic DNA. Autoradiogram of BamHI-digested mouse genomic DNA (10 μg) separated on a 0.8%
agarose gel and hybridized with a human-specific IKBKAP radiolabeled probe. The transgene number was estimated by comparing the intensity of the hybridized
bands to the controls shown. **For TgFD5, only 1 μg of genomic DNA was used.
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isoforms between an FD patient and the TgFD1 mouse, for
which matching tissue samples were available. The splicing
efficiency is significantly decreased in the neuronal tissues
compared to the nonneuronal tissues in both the FD patient
tissue and the FD transgenic mouse tissue. The correspondence
of the splicing pattern in heart, which displays more robust
splicing, and lung, in which splicing is poor, is also notable.
These results demonstrate that these transgenic animals will be
extremely valuable for testing not only kinetin, but also other
drugs that modify human splicing. Further, our demonstration
that the factors governing tissue-specific splicing are conserved
suggests that this mouse model will be useful for unraveling the
complexities of mammalian splicing regulation.
Discussion
The availability of the human genome sequence allows the
easy and rapid identification of large genomic BAC clones
containing specific genes of interest that can be used for the
production of transgenic mice for the study of both human
disease and basic biological processes. Using large sequence
BACs for transgenes is often preferable since genes are intro-
duced in the context of their surrounding genomic sequences,
including regulatory sequences and developmental or tissue-
specific promoter sequences. In this study, use of a BAC was
crucial to introduce all cis-acting splicing signals. A variety of
homologous recombination techniques have been developed for
accurate and subtle manipulation of large genomic clones, such
as BACs, PACs, and YACs [18,21–23]. We found the intro-
duction of a point mutation into a 172-kb BAC to be technically
challenging; however, the need for more accurate and sophis-
ticated murine models that recapitulate important aspects of
human disease pathology will no doubt increase the use of these
technologies.In this paper we describe the generation of a transgenic
mouse model that expresses human IVS20+6T→C IKBKAP
and models the tissue-specific variability of IKBKAP exon 20
skipping seen in FD patients. The use of transient expression of
the BAC construct in cultured mouse cells allowed us to con-
firm expression of human IKBKAP from the BAC construct
prior to commencing with transgenic mouse production. Such a
precautionary step is advisable to confirm that gene integrity has
been maintained during the recombination procedures. Our cell
culture experiments demonstrated not only exon 20 skipping as
a result of the FD mutation, but also splicing improvement
following kinetin treatment. Re-creation of these important
attributes of the cellular FD phenotype in a mouse cell line
indicated that the sequence elements that contribute to exon 20
missplicing are present and undisrupted in the modified FD
BAC and that the mechanism of kinetin's action is conserved
between the two species. Subsequent creation of the transgenic
animals and demonstration that the tissue specificity of the
splicing defect is also conserved highlight the general use-
fulness of this model for studies of tissue-specific splicing
regulation and therapeutic development.
The original microinjections yielded six positive transgenic
founder animals, and human IKBKAP expression was detected
in three of these. The transgene copy number in the expressing
and nonexpressing animals was variable, and high copy number
did not necessarily correlate with detectable IKBKAP expres-
sion, suggesting that expression may be dependent on integ-
ration site as much as copy number. Host sequences surround-
ing the transgene can cause reduced expression or even
transgene inactivation due to chromosomal positioning effects.
Large genomic fragments such as YACs and BACs are usually
insulated from such integration-dependent expression effects
[20]; however, it is possible that some regulatory sequences
were interrupted in our nonexpressing mice due to random
linearization of the BAC during microinjection and integration.
Fig. 4. (A) RT-PCR analysis of IKBKAP exon 20 splicing in multiple tissues from transgenic animals TgWT1, TgFD1, and TgFD2. Expression of the wild-type IKBKAP
in multiple tissues produces only the WT isoform. Expression of FD IKBKAP in multiple tissues in TgFD1 and TgFD2 shows variable tissue-specific splicing of exon 20.
(B) Comparison of IKBKAP exon 20 splicing in mouse and FD patient tissues. RT-PCR analysis of exon 20 splicing is shown for matching tissues samples from TgFD1
mouse and an FD patient. Plotted in the bar chart is the relative % of WT isoform spliced in each tissue from both the mouse and the patient samples. A similar pattern
of splicing is seen in both sample sets, with poorer exon 20 (% WT isoform) inclusion in neuronal tissues. The data for the human tissue samples are reproduced from
previously published results [10]. (C) RT-PCR analysis of endogenous Ikbkap expression in kidney and brain from transgenic mice TgWT1, TgFD1, and TgFD2.
394 M.M. Hims et al. / Genomics 90 (2007) 389–396The conservation of missplicing in the transgenic mice
carrying the FD mutation represents a major breakthrough in
our efforts to develop a model system to test the efficacy of
potential therapeutic agents. These animals can be used in
preclinical trials of pharmacological agents previously shown to
modify IKBKAP splicing, such as kinetin and EGCG [9,24].These humanized transgenic mice also provide a beautiful
model for studying tissue-specific alternative splicing. The
similar splicing patterns seen in humans and mice demonstrate
conservation of the mechanism responsible for tissue specifi-
city. We hypothesized previously that the neuronal loss seen in
FD is due to a drastic reduction of IKAP protein resulting from
395M.M. Hims et al. / Genomics 90 (2007) 389–396low exon 20 inclusion [10]. This transgenic mouse model can
be used to assess splicing patterns in individual cell types and
identify genes that control tissue specificity. Furthermore, exa-
mination of transgene splicing in various mouse strains may
lead to the identification of modifiers that influence human di-
sease severity.
Creation of a true mouse model of FD is complicated be-
cause we must model a tissue-specific decrease in IKAP
protein. The transgenic animals described in this study are a
crucial step in the development of a phenotypic model of the
human disease. Knockout of ELP1/IKBKAP has been shown to
be lethal in Drosophila melanogaster [12], and preliminary
results from our laboratory suggest that complete knockout of
Ikbkap causes embryonic lethality in mice (data not shown). It
will be of interest, therefore, to determine if the human wild-
type IKBKAP transgene will be capable of rescuing lethality
and ultimately if the FD transgene rescues lethality but leads to a
mouse with a phenotype that resembles familial dysautonomia.
The success of such a model system will certainly depend on
overall expression levels of IKBKAP in the mouse, since high
expression of even FD IKBKAPmight be sufficient to overcome
the absence of endogenous mouse Ikbkap expression. Thus, the
creation of many IKBKAP transgenic lines with varying copy
number and IKBKAP expression will be required to find an
animal line expressing IKBKAP at levels functionally equiva-
lent to those of endogenous mouse Ikbkap.
In summary, we have created several transgenic mice using a
human BAC containing full-length IKBKAP, into which we
inserted the IVS20+6T→C splicing mutation that is present in
all cases of familial dysautonomia. The FD mutation leads to
tissue-specific skipping of exon 20 in a pattern similar to that
seen in FD patient tissue. The creation of these mice is crucial
for testing potential therapeutics aimed at splicing modification,
and they are an important step in the development of a
phenotypic model of FD. Further, our demonstration that the
factors governing tissue-specific splicing are conserved sug-
gests that this mouse model will be useful for unraveling the
complexities of mammalian splicing regulation.
Methods and materials
Constructs
The recombination shuttle vector pKO3-KAN-FD was constructed
specifically to introduce the IVS20+6T→C mutation in the BAC clone
RP11-234B17. The vector pKO3 (obtained from Professor George Church) was
the basis for this construct and was modified in a number of ways: the 3′ region
of the CmR gene was removed to disrupt chloramphenicol resistance; a
kanamycin cassette (kan) derived from pACYC177 (NEB) was added to provide
kanamycin resistance, and a 1.7-kb genomic fragment of the IKBKAP gene
including the FD IVS20+6T→C mutation was subcloned from the IKBKAP 19-
21 minigene construct [9]. The plasmid pDF25 was obtained from Professor
David Sherratt and used unmodified.
Homologous recombination strategy
To introduce the point mutation in the BAC sequence we use a protocol
based on that described by Lalioti and Heath [18]. Briefly, we prepared 50 μl of
competent cells from 25 ml culture of DH10B cells containing BAC RP11-
234B17 (grown at 37°C with 20 μg/ml chloramphenicol to an OD600 of 0.6) andwashed them three times in ice-cold 10% glycerol. We cotransformed 750 ng
pKO3-KAN-FD and 250 ng pDF25 into 50 μl of freshly prepared competent
cells by electroporation (0.1-cm Bio-Rad Gene Pulsar cuvette, 1.8 kV, 25 μF,
200 ohms). We added 1 ml NZY+recovery medium and incubated the
transformed cells for 1.5 h at 30°C. We then plated the cells on chloramphenicol
and kanamycin plates and incubated them for 36 h at 30°C. We picked
individual colonies into 1 ml of LB, of which we plated 100 μl on
chloramphenicol and kanamycin plates and incubated them at 43°C overnight
to select for co-integrants. The following day, we selected the larger colonies
growing on a lawn of smaller colonies and prepared minipreps and glycerol
stocks of these clones. We tested these potential co-integrant clones by
sequencing to test for the presence of both wild-type and FD sequences. We
selected co-integrants that appeared “heterozygous” T/C at position IVS20+6,
for the counterselection phase. We then transformed 50 μl of freshly prepared
co-integrant-containing competent cells with 250 ng of pDF25 by electropora-
tion (0.1-cm Bio-Rad Gene Pulsar cuvette, 1.8 kV, 25 μF, 200 ohms). We added
1 ml NZY+recovery medium and incubated the cells for 1.5 h at 30°C. We then
plated 100-μl aliquots onto chloramphenicol/sucrose plates and allowed co-
integrants to resolve overnight at 43°C. We picked and streaked multiple
colonies on chloramphenicol/sucrose plates and incubated overnight at 30°C to
select for single colonies. We next selected the larger colonies and they were
streaked onto both chloramphenicol/sucrose and kanamycin/chloramphenicol/
sucrose plates and incubated overnight at 30°C. Only colonies that grew on
chloramphenicol/sucrose and not on kanamycin/chloramphenicol/sucrose plates
were considered to be resolved BACs. Resolved constructs were sequenced to
confirm resolution and the presence or absence of the FD IVS20+6T→C
mutation. The integrity of the resolved FD BAC was tested by end sequencing
with T7 (5′-TAATACGACTCACTATAGGG) and Sp6 (5′-ATTTAGGTGA-
CACTATAG) primers and by restriction digestion comparison with the original
unmodified BAC RP11-234B17. Restriction digests were carried out with SmaI
and XhoI and run on a 1% ethidium bromide-stained agarose gel.
BAC transfections and tissue culture
Mouse N2A cells were grown in 1:1 DMEM:HAMS, supplemented with
2 mM L-glutamine, 1% penicillin/streptomycin, and 10% fetal bovine serum.
BAC DNAwas purified using a Qiagen large construct kit, and 1–4 μg of BAC
DNA was transfected into mouse N2A cells using Lipofectamine 2000
transfection reagent (Invitrogen). HEK cells were grown in DMEM
supplemented with 2 mM L-glutamine and 1% penicillin/streptomycin and
10% fetal bovine serum. Where noted, cells were incubated with of 100 μM
kinetin solution (Sigma). Seventy-two hours posttransfection all cells were
harvested and total RNA was extracted using Tri Reagent (MRC).
Generation of transgenic mice
BAC transformed bacterial cultures were grown at 30°C for 18 h. BACDNA
was isolated using anion-exchange columns (Nucleobond; BD Biosciences).
Purified DNAwas quantified by absorbance and analyzed by gel electrophoresis
and then diluted into injection buffer [25] at 1 ng/μl. Transgenics were produced
by standard methods [26], briefly: C57/BL6/N embryos were harvested from
superovulated and mated females (Taconic and in-house). DNA solution was
injected into a pronucleus of selected embryos that were then allowed to
continue developing overnight. Those that advanced to the two-cell stage were
surgically transferred to the oviducts of pseudopregnant outbred (Charles River
or Taconic) recipient females. Resulting pups were weaned between 21 and 28
days after birth and tail biopsies were taken. Animals were treated in accordance
with all relevant NIH guidelines.
Transgene analysis
Transgenic founders were identified by PCR using human-specific primers
to IKBKAP intronic sequences TgProbe1F (5′-GCCATTGTACTGTTTGC-
GACT) and TgProbe1R (5′-TGAGTGTCACGATTCTTTCTGC). The trans-
gene copy number in positive founder animals was determined by Southern blot
using the same human-specific primers, TgProbe1F/TgProbe1R, to generate a
213-bp α-32P-radiolabeled probe. Genomic DNA from potential founder mouse
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(Qiagen). A total of 10 μg of genomic DNA from each sample was digested with
BamHI (NEB) overnight and separated on a 0.8% agarose gel. Copy number
was estimated by comparing the intensity of the hybridized IKBKAP fragment in
nontransgenic mice spiked with known quantities of the BAC clone with that of
the same IKBKAP fragment present in the transgenic samples using ImageQuant
TL software (Amersham Bioscience). Additionally copy number was also
estimated by quantitative PCR analysis on the same genomic DNA samples
using the Bio-Rad iCylcer, SYBR-Green supermix (Bio-Rad), and the primers
TgProbe1F/TgProbe1R [19]. Copy number was estimated by comparing the
amplification cycle thresholds attained in the transgenic mouse samples with
human genomic samples (considered as two copies).
RT-PCR analysis of spliced isoforms
Reverse transcription was performed using 1 μg total RNA, oligo(dT)
primer, and Superscript III reverse transcriptase (Invitrogen). PCR was per-
formed using the cDNA equivalent of 100 ng of starting RNA in a 40-μl
reaction, by use of Taq polymerase (Roche) and 30 amplification cycles (94°C
for 30 s, 58°C for 30 s, 72°C for 30 s). Human-specific IKBKAP primers Hs-sp-
Ex19F (5′-AGCAGCAATCATGTGTCCCA) and Hs-sp-Ex22R (5′-GTGA-
CATCTTCTTCTTTCAA) were used to amplify human IKBKAP. Mouse-
specific primers Mm-sp-Ex19F, 5′-AGTGGCAGTCATGAGGCCAG, and
Mm-sp-Ex22R, 5′-GTGACATCTTCTTCCCTGAG, were used to amplify
endogenous mouse Ikbkap transcripts. PCR products were separated on 1.5%
agarose gels and stained with ethidium bromide. The relative amounts of WT
and MU IKBKAP spliced isoforms in a single PCR were determined using an
Alpha 2000 image analyzer (Bio-Rad) and ImageQuant QL software (Amer-
sham), using the integrated density value for each band as previously described
[10], and the relative proportion of the WT isoform detected in a sample was
calculated as a percentage. All PCR products were sequenced to confirm
identity.
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